Medical Health & Life Science Research News

New report: Global angina pectoris drugs market: latest trends and future outlook by 2021

Technavio Announces the Publication of its Research Report – Global Angina Pectoris Drugs Market 2017-2021

- Advertisement -
- Market Research Pro -

Technavio recognizes the following companies as the key players in the global angina pectoris drugs market: AstraZeneca, Gilead, Novartis, and Pfizer.Other Prominent Vendors in the market are: Bayer HealthCare, Bristol-Myers Squibb, GlaxoSmithKline, Merck , Mylan, and Teva Pharmaceutical.Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is launch of novel pharmacologic agents. There has been a continuous unmet demand for therapeutics in the angina pectoris drugs market.

This, in turns, paves the way for entry of novel therapeutic agents in the market. Along with traditional therapeutic agents, trimetazidine, ivabradine, fasudil, and ranolazine represent a promising new therapeutic approach for the treatment of angina pectoris.

- Advertisement -
- Market Research Pro -

Ranolazine, an antianginal agent, has been the first agent from any new drug class to be approved by the FDA for the treatment of angina pectoris.”

Request Sample of Report at marketreportscenter.com/request-sample/554616

According to the report, one driver in the market is increase in chronic diseases. Chronic diseases such as diabetes, high blood pressure, and obesity are some of the potential factors leading to angina pectoris.

There has been a continuous rise in cases of these chronic diseases and some of them, such as diabetes, have turned into an epidemic, leading to huge concern from healthcare professionals across the globe. Diabetes increases the risk of developing number of serious health issues.

Constant high blood glucose can lead to severe health conditions and affects eyes, heart and blood vessels, nerves, teeth, and kidneys.Further, the report states that one challenge in the market is highly genericized market. The angina pectoris drugs market is highly generalized, i.e., the generic version of the drugs have captured a huge portion of the market.

The cost-effectiveness and high affordability of these generic drugs attracts huge support from various government and non-government organizations, this will further lead to the market penetration of the generic drugs. However, this has increased the price competition in the industry and decreased the overall revenue generated by top companies in the branded drugs market.The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry.

The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
About Angina Pectoris Drugs Angina is a type of chest pain or discomfort caused due to a coronary heart disease, specifically due to reduced blood flow to the heart. For angina pectoris drugs market, beta blockers remain the most preferred line of treatment.

However, the treatment market witnesses a strong presence of other drug classes such as calcium channel blockers. Though the market is fragmented, large players such as AstraZeneca, Gilead, Novartis, and Pfizer hold significant positions.

Access Report at marketreportscenter.com/request-discount/554616

Technavio’s analysts forecast the global angina pectoris drugs market to grow at a CAGR of 4.05% during the period 2017-2021.Covered in this report
The report covers the present scenario and the growth prospects of the global angina pectoris drugs market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs.The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEATechnavio's report, Global Angina Pectoris Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years.

The report also includes a discussion of the key vendors operating in this market.

Know more about report at marketreportscenter.com/reports/55…-market-2017-2021

Key vendors
• AstraZeneca
• Gilead
• Novartis
• PfizerOther prominent vendors
• ABayer HealthCare
• Bristol-Myers Squibb
• GlaxoSmithKline
• Merck
• Mylan
• Teva PharmaceuticalMarket driver
• Increase in chronic diseases
• For a full, detailed list, view our report Market challenge
• Highly genericized market
• For a full, detailed list, view our report Market trend
• Launch of novel pharmacologic agents
• For a full, detailed list, view our report Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?

News From

Market Reports Center - One Stop Shop for all market research needsMarket Reports Center
Category: Market Research Publishers and RetailersCompany profile: Market Reports Center is an e-commerce platform obliging the needs of knowledge workers, experts, professionals who are subject to market research information for their work, or to make strategic business decisions. We are dedicated to create a comprehensive offering of market research which is accurate, credible and affordable. Market Reports Center currently has more than 1,20,000 plus titles and 30+ Publishers on our platform and growing consistently. We cover more than 35 industry verticals ...